Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cyclophosphamide + Peg-interferon alfa-2a + Retifanlimab + SV-BR-1-GM |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Peg-interferon alfa-2a | Pegasys | peginterferon alfa-2a|pegylated interferon alfa-2a|PEG-IFNA2a | Pegasys (peg-interferon alfa-2a) comprises interferon alfa-2a conjugated to polyethylene glycol (PEG), which may decrease tumor cell proliferation and enhance anti-tumor immune response (NCI Drug Dictionary). | |
Retifanlimab | Zynyz | MGA 012|INCMGA00012|MGA012|retifanlimab-dlwr | Immune Checkpoint Inhibitor 149 PD-L1/PD-1 antibody 121 | Zynyz (retifanlimab) is a humanized IgG4 monoclonal antibody that targets PD-1 (PDCD1) and inhibits binding of the PD-L1 (CD274) ligand, potentially resulting in enhanced anti-tumor immune response (AACR; Cancer Res 2019;79(13 Suppl):Abstract nr CT085). Zynyz (retifanlimab) is FDA approved for use in adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma (FDA.gov). |
SV-BR-1-GM | Bria-IMT | SV-BR-1-GM is a vaccine comprising hormone receptor-negative, ERBB2 (HER2)-positive breast cancer cells engineered to secrete GM-CSF, which may induce an antitumor immune response (PMID: 29867922). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06072612 | Phase III | Cyclophosphamide + Peg-interferon alfa-2a + Retifanlimab + SV-BR-1-GM Cyclophosphamide + Peg-interferon alfa-2a + SV-BR-1-GM | Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer. (BRIA-ABC) | Recruiting | USA | 0 |